Efficacy and Safety of Rimexolone 1 % Ophthalmic Suspension vs 1% Prednisolone Acetate in the Treatment of Uveitis

Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis

“…After 4-6 weeks, the patient can be switched to less effective drugs (hence, drugs causing fewer adverse effects: e.g., rimexolone) [35,45,46] (IA). In individual cases, the lesser efficacy of the anti-inflammatory preparations needs to be weighed against the problems associated with more frequent application and compliance.…”

Efficacy and safety of 1% rimexolone versus 1% prednisolone acetate in the treatment of anterior uveitis ? a randomized triple masked study

“…Topical corticosteroids, including dexamethasone, prednisolone, hydrocortisone and fluorometholone are the most frequently used drugs and among them, prednisolone acetate is most preferred. The effects of corticosteroids on target cells, include inhibition of inflammatory mediator production, inhibition of inflammatory/immune cell function, alteration of lymphoid cell trafficking, inhibition of vasodilatation and inhibition of the wound healing process [2]. Topical corticosteroids, though effective as anti-inflammatory agents, are associated with side effects including increase in the intraocular pressure (IOP) [3][4][5][6][7][8][9][10][11][12] and posterior subcapsular cataract formation from prolonged use [13].…”

Difluprednate 0.05% versus Prednisolone Acetate 1% for Endogenous Anterior Uveitis: Pooled Efficacy Analysis of Two Phase 3 Studies

“…17 Rimexolone is another topical steroid observed in randomized trials to be clinically and statistically equivalent to prednisolone acetate in controlling uveitic inflammation. 18,19 Other topical steroids shown in previous randomized trials to be effective in the treatment of anterior uveitis are betamethasone phosphate, clobetasone butyrate, hydrocortisone, loteprednol etabonate, and tolmetin sodium dihydrate. [20][21][22][23][24] In other ophthalmic indications, less frequent dosing of topical ophthalmic medications has been reported to be one of the factors associated with better treatment compliance, which may provide an advantage for difluprednate with a four times daily initial therapy label.…”